In addition to CCR4 ligands, CCL18 and CCL26 are frequently elevated in CTCL serum, and lesions and have been associated with disease progression and adverse prognosis [50,51,61]. This evidence concerns the gene CCL26 and primary cutaneous T-cell non-Hodgkin lymphoma.